Novartis
18 links on this map: who funds them, what they touched, and who lobbied on it. Select anyone to move the map to them.
Start with
and connect to
Novartis
Federal lobbying records
Bills it lobbied on8 of 33
S 1096 Preserve Access to Affordable Generics and Biosimilars Act10 reports · On the floor calendarS 1095 Stop STALLING Act10 reports · On the floor calendarHR 1 An act to provide for reconciliation pursuant to title II of H. Con. Res. 149 reports · Became lawHR 3269 ETHIC Act8 reports · In committeeHR 1672 Maintaining Investments in New Innovation Act38 reports · In committeeS 832 EPIC Act of 202521 reports · In committeeHR 1492 To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program17 reports · In committeeHR 946 ORPHAN Cures Act11 reports · In committeeEvery link on this map
The same connections as a table, with the reason each one is here.
| S 1096 | Bills it lobbied on | Novartis named S 1096, “Preserve Access to Affordable Generics and Biosimilars Act”, in 10 lobbying reports. | 10 reports |
| S 1095 | Bills it lobbied on | Novartis named S 1095, “Stop STALLING Act”, in 10 lobbying reports. | 10 reports |
| HR 1 | Bills it lobbied on | Novartis named HR 1, “An act to provide for reconciliation pursuant to title II of H. Con. Res. 14”, in 9 lobbying reports. | 9 reports |
| HR 3269 | Bills it lobbied on | Novartis named HR 3269, “ETHIC Act”, in 8 lobbying reports. | 8 reports |
| HR 1672 | Bills it lobbied on | Novartis named HR 1672, “Maintaining Investments in New Innovation Act”, in 38 lobbying reports. | 38 reports |
| S 832 | Bills it lobbied on | Novartis named S 832, “EPIC Act of 2025”, in 21 lobbying reports. | 21 reports |
| HR 1492 | Bills it lobbied on | Novartis named HR 1492, “To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program”, in 17 lobbying reports. | 17 reports |
| HR 946 | Bills it lobbied on | Novartis named HR 946, “ORPHAN Cures Act”, in 11 lobbying reports. | 11 reports |
| Gregg Hart | Lawmakers it funded or lobbied | Novartis gave $9,500 to Gregg Hart, 2022–2026. | Got $9,500 |
| Joan Huffman | Lawmakers it funded or lobbied | Novartis gave $9,000 to Joan Huffman, 2021–2024. | Got $9,000 |
| Lois Kolkhorst | Lawmakers it funded or lobbied | Novartis gave $8,000 to Lois Kolkhorst, 2019–2025. | Got $8,000 |
| Rochelle Nguyen | Lawmakers it funded or lobbied | Novartis gave $8,000 to Rochelle Nguyen, 2023–2025. | Got $8,000 |
| Jane Nelson | Lawmakers it funded or lobbied | Novartis gave $7,500 to Jane Nelson, 2000–2018. | Got $7,500 |
| Drew MacEwen | Lawmakers it funded or lobbied | Novartis gave $6,000 to Drew MacEwen, 2017–2025. | Got $6,000 |
| Annette Cleveland | Lawmakers it funded or lobbied | Novartis gave $5,900 to Annette Cleveland, 2015–2023. | Got $5,900 |
| Destin Hall | Lawmakers it funded or lobbied | Novartis gave $5,000 to Destin Hall, 2023–2025. | Got $5,000 |
| Amy Klobuchar | Lawmakers it funded or lobbied | Amy Klobuchar leads 2 bills Novartis lobbied on. | Leads 2 of these bills |
| Jodey Arrington | Lawmakers it funded or lobbied | Jodey Arrington leads 2 bills Novartis lobbied on. | Leads 2 of these bills |